HC Wainwright Issues Positive Estimate for UNCY Earnings

Key Points

• HC Wainwright raised its Q1 2026 EPS estimate for Unicycive to ($0.05) from ($0.35) and projects a long-term rebound with EPS forecasts turning positive to $1.60 in FY2028 and $7.45 in FY2030.
• Missed quarterly results: the company reported ($0.82) EPS versus a ($0.46) consensus, its stock opened at $6.93 (down ~2.7%), and the shares remain volatile with a 12‑month range of $3.71–$11.00 and a market cap around $175M.
• Analyst and investor views are mixed—four Buy ratings and one Sell with an average target of $27.67—while institutional ownership is about 40.4% and retail interest recently spiked roughly 150%, increasing short‑term momentum risk.

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2026 EPS estimates for Unicycive Therapeutics in a note issued to investors on Tuesday, March 31st. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.05) for the quarter, up from their previous estimate of ($0.35). The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Unicycive Therapeutics' Q2 2026 earnings at ($0.52) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.76) EPS, FY2026 earnings at ($1.67) EPS, FY2027 earnings at ($0.90) EPS, FY2028 earnings at $1.60 EPS, FY2029 earnings at $5.70 EPS and FY2030 earnings at $7.45 EPS.

Several other analysts have also issued reports on UNCY. Westpark Capital started coverage on Unicycive Therapeutics in a report on Thursday, February 19th. They set a "buy" rating for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Unicycive Therapeutics in a research note on Friday, March 27th. Finally, Guggenheim dropped their target price on Unicycive Therapeutics from $46.00 to $40.00 and set a "buy" rating on the stock in a research report on Thursday. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $27.67.

Unicycive Therapeutics Stock Down 2.7%

Unicycive Therapeutics stock opened at $6.93 on Friday. The company's fifty day simple moving average is $6.67 and its 200-day simple moving average is $5.79. Unicycive Therapeutics has a 12 month low of $3.71 and a 12 month high of $11.00. The stock has a market cap of $174.91 million, a P/E ratio of -3.19 and a beta of 1.81.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.36).

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Millennium Management LLC acquired a new stake in shares of Unicycive Therapeutics in the 4th quarter valued at $5,856,000. Vivo Capital LLC boosted its holdings in Unicycive Therapeutics by 57.4% in the third quarter. Vivo Capital LLC now owns 1,789,916 shares of the company's stock worth $7,804,000 after purchasing an additional 652,901 shares in the last quarter. Cantor Fitzgerald L. P. acquired a new position in Unicycive Therapeutics during the fourth quarter worth $1,154,000. Squarepoint Ops LLC acquired a new position in Unicycive Therapeutics during the third quarter worth $512,000. Finally, OMERS ADMINISTRATION Corp bought a new position in Unicycive Therapeutics during the fourth quarter valued at about $451,000. Institutional investors and hedge funds own 40.42% of the company's stock.

Unicycive Therapeutics News Summary

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: Guggenheim retained a "Buy" rating while lowering its price target from $46 to $40 — the new PT still implies a very large upside vs. the current share price, which can support bullish sentiment if the company hits clinical milestones. Guggenheim price target cut to $40
• Positive Sentiment: Noble Financial nudged a number of near-term quarterly estimates higher — Q1 2026 from ($0.47) to ($0.45), Q2 2026 from ($0.54) to ($0.52), and Q3 2026 from $0.74 to $0.79 — suggesting modestly improving near-term operational expectations. MarketBeat: Noble Financial raises Q1–Q3 estimates
• Positive Sentiment: Retail interest has surged this week (reports say a ~150% spike in retail buzz), which can produce sharp, momentum-driven upside ahead of binary events such as drug-approval outcomes. This increases short-term volatility and the chance of rapid price moves. UNCY retail buzz explodes 150%
• Neutral Sentiment: Consensus estimates remain mixed: market consensus for the current full year is still negative (around -$0.23 EPS), which contrasts with some analysts' multi-quarter positive numbers — creating uncertainty about the timing and sustainability of profitability. MarketBeat consensus data
• Negative Sentiment: Noble Financial lowered its FY2026 outlook (from $1.02 to $0.85) and reduced Q4 2026 estimates (from $1.11 to $0.87), which is a downgrade to longer-term earnings optimism and could weigh on the stock if investors focus on the reduced full-year trajectory. MarketBeat: Noble lowers FY/Q4 estimates

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.